Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer

J Clin Oncol. 2005 Apr 1;23(10):2434-5; author reply 2435. doi: 10.1200/JCO.2005.05.890.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Body Mass Index*
  • Cachexia
  • Clinical Trials as Topic
  • Drug Resistance, Neoplasm
  • Humans
  • Male
  • Multicenter Studies as Topic
  • Multivariate Analysis
  • Obesity / complications
  • Prognosis
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology*
  • Survival Analysis